EGFR and colorectal cancer: This inhibitor shows potent antitumor activity in several preclinical models of pancreatic and colorectal cancer, especially when combined either with cetuximab, a monoclonal antibody against the EGFR, or with BYL‐719, a potent PI3Kα inhibitor.